131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
Condition(s):Relapsed or Refractory Marginal Zone B-cell LymphomaLast Updated:September 5, 2012Unknown status
Hide Studies Not Open or Pending
Condition(s):Relapsed or Refractory Marginal Zone B-cell LymphomaLast Updated:September 5, 2012Unknown status
Condition(s):Marginal Zone Lymphoma; B-cell LymphomaLast Updated:October 16, 2019Completed
Condition(s):Marginal Zone Lymphoma of Ocular AdnexalLast Updated:May 18, 2023Active, not recruiting
Condition(s):Antibiotics-unresponsive MALT Lymphoma; Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma; Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT)Last Updated:October 27, 2020Unknown status
Condition(s):Marginal Zone Lymphoma; Nodal Marginal Zone Lymphoma; Splenic Marginal Zone LymphomaLast Updated:May 10, 2023Active, not recruiting
Condition(s):Marginal Zone Lymphoma; Follicular LymphomaLast Updated:March 21, 2024Completed
Condition(s):Marginal Zone Lymphoma; MZLLast Updated:June 6, 2023Completed
Condition(s):Relapsed/Refractory Follicular Lymphoma; Marginal Zone LymphomaLast Updated:March 13, 2024Recruiting
Condition(s):Mucosa-Associated Lymphoid Tissue LymphomaLast Updated:December 8, 2016Unknown status
Condition(s):Gastric Mucosa-Associated Lymphoid Tissue LymphomaLast Updated:September 28, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.